For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...
In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...
Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...
August 28, 2012 (Munich, Germany) — The debate as to whether platelet function should be routinely measured in patients undergoing PCI has been raised again with two new studies presented at the ...
BRAINTREE, Mass., Nov. 20, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient ...
The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn't answer any of the key questions about the ...
A new study successfully identifies new genetic variants involved in the formation of platelets and more importantly, defines how genes near these variants affect platelet size and number using a ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
The global platelet function test market is projected to be valued at USD 1.38 billion in 2025 and is expected to reach USD 2.61 billion by 2035, registering a CAGR of 6.3% during the forecast period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results